Zealand Pharma AS (ZLDPF)
(Delayed Data from OTC)
$93.70 USD
-3.30 (-3.40%)
Updated Jun 7, 2024 01:23 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Zealand Pharma AS falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 50 | 15 | 47 | 54 | 6 |
Cost Of Goods | NA | 0 | 19 | 14 | 0 |
Gross Profit | NA | 15 | 28 | 40 | 6 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 133 | 195 | 162 | 94 |
Income After Depreciation & Amortization | 0 | -119 | -167 | -121 | -88 |
Non-Operating Income | NA | 19 | 7 | 0 | 2 |
Interest Expense | NA | 38 | 3 | 8 | 1 |
Pretax Income | NA | -138 | -163 | -129 | -86 |
Income Taxes | NA | -1 | -1 | 1 | -1 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -102 | -137 | -162 | -130 | -86 |
Extras & Discontinued Operations | 0 | -33 | 0 | 0 | 0 |
Net Income (GAAP) | -102 | -170 | -162 | -130 | -86 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -102 | -161 | -115 | -88 |
Depreciation & Amortization (Cash Flow) | NA | 17 | 6 | 7 | 0 |
Income After Depreciation & Amortization | 0 | -119 | -167 | -121 | -88 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 56.57 | 46.20 | 42.87 | 38.37 | 33.80 |
Diluted EPS Before Non-Recurring Items | -1.81 | -2.95 | -3.78 | -3.38 | -2.53 |
Diluted Net EPS (GAAP) | -1.81 | -3.68 | -3.78 | -3.38 | -2.54 |
Fiscal Year end for Zealand Pharma AS falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 2.20 | 3.35 | 43.15 | 1.52 | 1.96 |
Cost Of Goods | NA | NA | 0.75 | 0.00 | 0.00 |
Gross Profit | NA | NA | 42.39 | 1.52 | 1.96 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 35.78 | 30.07 | 26.27 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 6.61 | -28.55 | -24.31 |
Non-Operating Income | NA | NA | 4.88 | 1.72 | 1.07 |
Interest Expense | NA | NA | 0.86 | 20.08 | 4.91 |
Pretax Income | NA | NA | 10.63 | -46.91 | -28.15 |
Income Taxes | NA | NA | -0.19 | -0.23 | -0.24 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -33.30 | -38.22 | 10.83 | -46.68 | -27.90 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -33.30 | -38.22 | 10.83 | -46.68 | -27.90 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 61.63 | 57.55 | 60.28 | 58.09 | 52.00 |
Diluted EPS Before Non-Recurring Items | -0.54 | -0.66 | 0.18 | -0.80 | -0.54 |
Diluted Net EPS (GAAP) | -0.54 | -0.66 | 0.18 | -0.80 | -0.54 |